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Abstract
Background: Recent genome-wide association studies (GWAS) have found a single nucleotide polymorphism (SNP,
rs2274223 A.G) in PLCE1 to be associated with risk of gastric adenocarcinoma. In the present study, we validated this
finding and also explored the risk associated with another unreported potentially functional SNP (rs11187870 G.C) of
PLCE1 in a hospital-based case-control study of 1059 patients with pathologically confirmed gastric adenocarcinoma and
1240 frequency-matched healthy controls.
Methodology/Principal Findings: We determined genotypes of these two SNPs by the Taqman assay and used logistic
regression models to estimate odds ratios (ORs) and 95% confidence intervals (95% CI). We found that a significant higher
gastric adenocarcinoma risk was associated with rs2274223 variant G allele (adjusted OR=1.35, 95% CI=1.14–1.60 for
AG+GG vs. AA) and rs11187870 variant C allele (adjusted OR=1.26, 95% CI=1.05–1.50 for CG+CC vs. GG). We also found
that the number of combined risk alleles (i.e., rs2274223G and rs11187870C) was associated with risk of gastric
adenocarcinoma in an allele-dose effect manner (Ptrend=0.0002). Stratification analysis indicated that the combined effect of
rs2274223G and rs11187870C variant alleles was more evident in subgroups of males, non-smokers, non-drinkers and
patients with gastric cardia adenocarcinoma. Further real-time PCR results showed that expression levels of PLCE1 mRNA
were significantly lower in tumors than in adjacent noncancerous tissues (0.01960.002 vs. 0.00860.001, P,0.05).
Conclusions/Significances: Our results further confirmed that genetic variations in PLCE1 may contribute to gastric
adenocarcinoma risk in an eastern Chinese population.
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Introduction
Gastric cancer is one of the leading causes of cancer-related
deaths in the world, accounting for 8% of the total new cases and
10% of total deaths worldwide in 2008 [1]. The high incidence
occurs particularly in areas of East Asia (especially China and
Japan), Eastern Europe and parts of Central and South America
[2]. In China, gastric cancer remains to be a major cancer burden,
and two thirds of the incident cases take place in rural areas,
ranking the third most common cancer in China [3]. Although the
mortality rate has declined due to improvement in social-economic
environment, lifestyle, nutrition intake and health care system,
there are still urgent needs for early diagnose and cancer
prevention because of poor prognosis and lack of novel treatments
for this disease.
Gene-environment interaction continues to be an acknowledged
cause for gastric cancer carcinogenesis [4]. Previously established
environmental factors associated with risk of gastric cancer include
Helicobacter pylori infection [5], dietary habits (e.g., high intake of
salt-preserved and nitrated foods), smoking, pernicious anemia and
a history of partial gastrectomy [6]. Extensive epidemiological
studies have demonstrated that genetic variants, particularly single
nucleotide polymorphisms (SNPs), are likely to modulate the effect
of environmental risk factors through modifying functions of
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e31932various biological pathways involved in gastric carcinogenesis in
response to environmental exposure.
Previous molecular epidemiologic studies on associations
between SNPs and risk of gastric cancer primarily focused on
those involving inflammatory cytokines (like IL-1b and TNF-a)
[7], metabolic enzymes (such as the cytochrome P450 superfamily
[8], glutathione S-transferase family [9], folate metabolism related
enzymes [10]) and DNA repair genes [11,12]. Recently, two
genome-wide association studies (GWASs) [13,14] have reported a
shared susceptible locus at 10q23 (rs2274223A.G, exon 26) in the
PLCE1 gene associated with risk of gastric adenocarcinoma. In one
GWAS, PLCE1 rs2274223 was reported to be associated with risk
of both esophageal squamous cell carcinoma and gastric cardia
adenocarcinoma in northern Chinese populations [13], and the
other GWAS reported a similar finding in ethnic Chinese
populations in other geographic areas [14], in which an
association was found only in gastric cardia adenocarcinoma but
not gastric noncardia adenocarcinoma. Such a finding was
replicated in another independent case-control study of gastric
cancer in a Chinese population [15].
The PLCE1 gene encodes phospholipase C [16] that catalyzes
the hydrolysis of polyphatidylinositol 4,5-bisphosphate into second
messengers such as inositol 1,4,5-trisphosphate and 4,5-diacylgly-
cerol [17,18]. The phospholipase C also functions as an effector
protein in Ras-, Rho- and Gabc-mediated signaling [19], a mediator
of extracellular signaling, further affecting cell motility, fertilization
and sensory transduction [20]. Therefore, we hypothesized that
SNPs in the PLCE1 gene are associated with gastric cancer risk in
eastern Chinese populations. To test this hypothesis, in addition to
the reported rs2274223A.G, we also selected another potentially
functional SNP rs11187870G.Ci nt h e3 9UTR miRNA binding
site of PLCE1 identified by HapMap and SNPinfo (http://snpinfo.
niehs.nih.gov/), which is in incomplete linkage disquilibrium (LD)
with rs2274223 (r
2=0.65, D’=0.92) as well as in high LD with
three of the novel SNPs revealed in GWAS of gastric cancer
(rs753724 G.T, r
2=0.823; rs11187842 C.T, r
2=0.823;
rs3781264 T.C, r
2=0.823) [14]. We further measured the PLCE1
mRNAexpressionsin pairedtissue samples of differentgenotypes to
investigate the possibly functional role of variant rs2274223 in the
etiology of gastric adenocarcinoma.
Materials and Methods
Study Population
The study population consisted of 1,059 Han Chinese patients
with newly diagnosed and histopathologically confirmed gastric
cancer from Fudan University Shanghai Cancer Center (Shang-
hai, China) between 2009 and 2010. All patients came from the
Eastern China, including Shanghai, Jiangsu and the surrounding
regions. Exclusion criteria included gastric adenosquamous
carcinoma, squamous cell carcinoma, neuroendocrine tumor,
stromal tumor, metastasized cancer from other organs and
esophageal tumors. In addition, 1,240 cancer-free controls were
recruited from Taizhou Longitudinal Study (TZL) at the same
period with the selection criteria including no individual history of
cancer [21]. These cancer-free Han Chinese controls were
frequency matched to the cases on age (65 years) and sex. At
recruitment, each participant was personally interviewed to gather
demographic data (such as age, sex, and ethnicity) and
environmental exposure history, including smoking and alcohol
consumption. After interview, each participant donated approx-
imately 10 mL of blood, of which 1 mL was used for genomic
DNA extraction. This study was approved by the Institutional
Review Board of Fudan University Shanghai Cancer Center.
SNP Selection and Genotyping
PLCE1 is located on chromosome 10q23 with 32 exons
(NM_001165979.1), encoding for a protein of 2286 amino acids
(BC144286.1) (NCBI dbSNP database: http://www.ncbi.nlm.nih.
gov/). Besides the non-synonymous rs2274223 SNP identified in
the published GWAS [13,14], we searched the NCBI dbSNP
database for other common, potentially functional SNPs of PLCE1
by using a set of tools at the website SNPinfo (http://snpinfo.niehs.
nih.gov/). Potentially functional SNPs were defined as non-
synonymous SNPs with minor allele frequency (MAF) .5%, SNPs
located at the 59 UTR, 39UTR and splice sites. The rs11187870
SNP located in the miRNA binding site of the 39UTR and
rs3203713 of the 59 UTR were selected by SNPinfo, but
rs3203713 was not detected in Asians as listed in the NCBI
dbSNP database, nor in our study population (data not shown). As
a result, we genotyped two SNPs (rs2274223A.G and
rs11187870G.C) of PLCE1 using genomic DNA isolated from
blood samples using the QIAamp DNA blood maxi kit (Qiagen,
Valencia, CA). Genotyping for SNPs rs2274223 and rs11187870
was performed using the Taqman assays (Applied Biosystems,
Foster City, CA) with a 7900 HT sequence detector system
(Applied Biosystems). As recommended by the company, four
negative controls (without DNA template) and two duplicated
samples were included in each 384-plate for the quality control.
The assays were repeated for 5% of the samples, and the results
were 100% concordant.
Tissue Preparation
According to genotyping results of rs2274223, we further
performed the real-time PCR analysis by using surgically removed
tissues from 48 patients with different genotypes (including 17 AA,
15 AG and 16 GG genotype carriers). All of these patients had
undergone gastrectomy for gastric adenocarcinoma without
preoperative treatment and provided written informed consent.
Gastric adenocarcinoma tumor and adjacent normal tissues were
dissected and evaluated by a pathologist after surgery, transferred
into liquid nitrogen immediately after resection and stored at
280uC until use at Department of Pathology and Tissue Bank of
Shanghai Cancer Center, Fudan University. This use of these
specimens was approved by the institutional review board.
Real-Time PCR
RNA was extracted from samples of tumor and corresponding
normal tissues with the TRIzol reagent (Invitrogen) according to
the manufacturer’s instructions. One micrograms of each RNA
sample was subjected to reverse transcription (RT) with the
PrimeScriptH RT Master Mix system, according to the manufac-
turer’s instructions (TAKARA). The primers used for the real-time
RT-PCR were: 59-CCTGGGCATAAGCACTACCAAG-39 and
59-GTCTTGAGGATCAGAACCACTCC-39 for PLCE1;5 9-
AGCCTCGCCTTTGCCGAT-39 and 59 CTTCTGACC-
CATGCCCACC 39 for b-actin. A total of 1 ml of the resulting
cDNA reaction mixture was used to set up the real-time PCR,
using the ABI Prism 7900 HT Sequence Detection System with
the following cycling conditions: (i) 30 s at 95uC and (ii) 40 cycles,
with every cycle consisting of 5 s at 95uC, 30 s at 60uC. Each
sample was run in triplicate, and b-actin was used as an internal
reference under the same experimental conditions. The PCR
products were analyzed by melting curves and agarose gel
electrophoresis to monitor specificity. The values were obtained
through normalizing PLCE1 copies to b-actin copies. For
each sample, the difference in threshold cycles for each PLCE1
copy was calculated by 2-DCT (DCT=Avg. PLCE1 CT - Avg.b-
actin CT). 2-DDCT was also calculated and DDCT was
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DCTtumor=Ct tumor/PLCE1-Cttumor/b-actin and DCTnormal=
Ctnormal/PLCE1-Ctnormal/b-actin.
Statistical Analysis
Pearson’s x
2 test was used to evaluate differences in the
distributions of categorical variables, including selected demo-
graphic variables, the known risk factors, such as smoking and
drinking status, as well as frequencies of PLCE1 genotypes between
the cases and controls. The Hardy–Weinberg equilibrium of the
control genotype distributions was tested by a goodness-of-fit x
2
test. Both univariate and multivariate logistic regression analyses
were conducted to estimate odds ratios (ORs) and 95% confidence
intervals (CIs) for associations between different genotypes and risk
of gastric cancer and were stratified by age, sex, smoking/drinking
status and primary tumor site. The homogeneity tests were also
performed to test for any difference in the risk estimates between
the strata. Haplotype frequencies and individual haplotypes were
estimated and analyzed using Statistical Analysis Software PROC
HAPLOTYPE. Paired-Sample Student’s t test was applied for the
comparison of mRNA levels between paired samples of different
genotype. All tests were two-sided using the Statistical Analysis
Software (v.9.1 SAS Institute, Cary, NC), and P,0.05 was
considered statistical significant.
Results
Characteristics of the Study Population
As shown in Table 1, the final analysis included 1,059 cases
and 1,240 controls who were adequately frequency matched by
age and sex (P=0.425 and 0.117, respectively). The mean age was
almost the same between cases (58.40611.32 years) and controls
(58.40611.99 years) The cases had more smokers and drinkers
(38.1% and 23.7%, respectively), compared with the controls
(34.0% and 18.1%, respectively; P=0.041 and P=0.001,
respectively). In addition, more cases reported to be heavy
smokers than did the controls (21.72% vs. 17.34% for ,22.5
pack-years; P=0.028). These variables (i.e., age, sex, smoking
status and drinking status) were further adjusted for in later
multivariate logistic regression analyses. Of the cases, 284
(26.82%) had cardia gastric cancers, and 775 (73.18%) had non-
cardia gastric cancers.
Associations between PLCE1 Genotypes and Risk of
Gastric Cancer
Genotype distributions of the two selected SNPs (rs2274223 and
rs11187870) in cases and controls are summarized in Table 2.
The observed genotype frequencies for the two SNPs agreed with
the expected from the Hardy–Weinberg equilibrium in the
controls (P=0.224 for rs2274223 and P=0.688 for rs11187870).
The genotype distributions between the cases and controls were
significantly different for both rs2274223 and rs11187870
(P=0.0012 and P=0.010, respectively). In the dominant model,
a significantly increased risk of gastric cancer was associated with
variant genotypes (AG+GG) of rs2274223 with an adjusted OR of
1.35 (95% CI=1.14–1.60) and (CG+CC) of rs11187870 with an
adjusted OR of 1.26 (95% CI=1.05–1.50), compared with the
wild-type homozygous genotypes, respectively. In addition, the
variant rs2274223 G and rs11187870 C alleles were significantly
associated with increased risk of gastric cancer (adjusted
OR=1.26, 95% CI=1.10–1.45 for rs2274223 G allele; adjusted
OR=1.22, 95% CI=1.05–1.42 for rs11187870 C allele,
respectively), with P values of 0.001 and 0.01, respectively.
To explore the independence of rs2274223 and rs11187870
with gastric cancer risk, they were simultaneously included in a
logistic regression model with adjustment for other covariates. The
strength of the association for rs2274223 (OR=1.39, 95%
CI=1.07–1.81) was almost unchanged, while the association for
rs11187870 (OR=0.96, 95% CI=0.73–1.26) was attenuated,
indicating that only rs2274223 was independently associated with
gastric cancer risk. Finally, we also performed a mini-meta analysis
of PLCE1 rs2274223 with our and the published three other
studies (Figure 1). Consistently, we found that PLCE1 rs2274223
variant G allele was significantly associated with an increased risk
of gastric cancer (the pooled OR=1.43; 95% CI=1.29–1.58 for
the AG genotype and OR=2.00; 95% CI=1.62–2.46 for the GG
genotype, compared with the AA genotype) based on 7115 cases
and 16201 controls in our pooled analysis.
We then categorized the putative risk alleles of the two SNPs
into the number of combined variant alleles (i.e., rs2274223G and
rs11187870C) to further analyze their possible joint effect and
potential locus-locus interaction of PLCE1 SNPs on risk of gastric
cancer. As shown in Table 2, when we trichotomized the subjects
into three groups according to the number of combined variant
alleles, the number of observed risk alleles was associated with
gastric cancer risk in an allele-dose response manner (P for
trend=0.0002). Specifically, when the ‘‘0’’ risk allele group was
used as the reference, the increased risk of gastric cancer was 1.36
fold (95% CI=1.14–1.62) for those who carried ‘‘1–2’’ risk alleles
and the risk increased to 1.43 fold (95% CI=0.97–2.09) for those
who carried ‘‘3–4’’ risk alleles. Because relatively fewer subjects
carried ‘‘3–4’’ risk alleles, we merged ‘‘1–2’’ and ‘‘3–4’’ into one
Table 1. Distributions of selected variables in GA cases and
cancer-free controls.
Variables Cases No. (%) Controls No. (%) P
a
All subjects 1,059(100) 1,240 (100)
Age, yr (Mean6SD)
b 58.40611.32 58.40611.99
#58 (median) 507 (47.9) 573 (46.2) 0.425
.58 (median) 552 (52.1) 667 (53.8)
Sex 0.117
Males 752 (71.0) 843 (68.0)
Females 307 (29.0) 397 (32.0)
Smoking status 0.041
Yes 403 (38.1) 421 (34.0)
No 656 (61.9) 819 (66.0)
Drinking status 0.001
Yes 251(23.7) 225 (18.1)
No 808 (76.3) 1015 (81.9)
Pack-years 0.028
0 656 (61.95) 819 (66.05)
#22.5 (mean) 230 (21.72) 215 (17.34)
.22.5 (mean) 173(16.33) 206 (16.61)
Tumor site
Cardia 284(26.82)
Non-cardia 775(73.18)
GA, gastric adenocarcinoma.
aTwo-sided x
2 test for distributions between cases and controls.
bData are mean 6 SD and P value from Student’s t test.
doi:10.1371/journal.pone.0031932.t001
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risk alleles exhibited a significantly increased risk of gastric cancer
(adjusted OR=1.37, 95% CI=1.16–1.62), compared with those
who did not carry any risk alleles. Then, we used this combined
group for further stratified analysis.
Stratification Analysis
As shown in Table 3, the stratification analysis indicated that
the risk associated with the combined rs2274223 variant AG/GG
genotypes and rs11187870 variant CG/CC genotypes was more
evident in males (adjusted OR=1.37, 95% CI=1.12–1.67 for
rs2274223 AG/GG genotypes; adjusted OR=1.33, 95%
CI=1.08–1.65 for rs11187870 CG/CC genotypes, respectively),
non-smokers (adjusted OR=1.45, 95% CI=1.17–1.79 for
rs2274223 AG/GG genotypes; adjusted OR=1.30, 95%
CI=1.04–1.62 for rs11187870 CG/CC genotypes, respectively),
non-drinkers (adjusted OR=1.38, 95% CI=1.14–1.66 for
rs2274223 AG/GG genotypes; adjusted OR=1.22, 95%
CI=1.00–1.48 for rs11187870 CG/CC genotypes, respectively)
and subjects with cardia cancer (adjusted OR=2.07, 95%
CI=1.59–2.70 for rs2274223 AG/GG genotypes; adjusted
OR=1.86, 95% CI=1.42–2.43 for rs11187870 CG/CC geno-
types) compared with those without any variant genotypes.
Consistently, the increased gastric cancer risk associated with
any ($1) of the variant risk alleles or genotypes was also more
pronounced among non-smokers (adjusted OR=1.51, 95%
CI=1.22–1.86) and non-drinkers (adjusted OR=1.40, 95%
CI=1.16–1.69), compared with those without any (0) variant risk
alleles. Additional analysis with groups of pack-years smoked did
not generate more striking data (data not shown) than did the
smoking status. Further homogeneity tests suggested that there
were no differences in the risk estimates between these strata
except for tumor site. There was no statistical evidence for
interactions between the variant genotypes and any of the tested
variables (i.e., age, sex, smoking status and alcohol consumption)
on risk of gastric cancer (data not shown).
Haplotype and Stratification Analyses
By using the SAS PROC HAPLOTYPE program, we estimated
four possible hapolotypes from the observed genotypes of the two
SNPs and assessed their associations with gastric cancer risk
(Table 4). When the most common haplotype Ars2274223
Grs11187870 was used as the reference, Grs2274223Crs11187870 and
Grs2274223Grs11187870 haplotypes were both associated with a
significantly increased risk of gastric cancer (adjusted OR=1.24,
95% CI=1.06–1.45, adjusted OR=1.34, 95% CI=1.04–1.72,
respectively), whereas subjects who carried the Ars2274223
Crs11187870 haplotype had non-significantly increased risk of gastric
cancer (adjusted OR=1.33, 95% CI=0,74–2.38), which may be
due to the limited sample size of this subgroup.
Table 2. Logistic regression analysis of associations between the genotypes of PLCE1 and GA risk.
Variants Genotypes
Cases
(N=1,059)
Controls
(N=1,240)
Crude OR
(95% CI) P
a
Adjusted OR
(95%CI)
b P
b
PLCE1 rs2274223
AA 600 (56.66) 791(63.79) 1.00 1.00
AG 399 (37.68) 390 (31.45) 1.35 (1.13–1.61) 0.0008 1.35 (1.13–1.61) 0.0008
GG 60 (5.66) 59 (4.76) 1.34 (0.92–1.95) 0.125 1.34 (0.92–1.96) 0.123
AG+GG 459 (43.34) 449 (36.2) 1.35 (1.14–1.59) 0.0005
d 1.35 (1.14–1.60) 0.0005
d
Allele A 1,599 (75.5) 1,972 (79.5) 1.00 1.00
G 519 (24.5) 508 (20.5) 1.26 (1.10–1.45) 0.001
f 1.26 (1.10–1.45) 0.001
f
PLCE1 rs11187870
GG 691 (65.25) 870 (70.2) 1.00 1.00
CG 329 (31.07) 335 (27.0) 1.24 (1.03–1.48) 0.022 1.24 (1.03–1.49) 0.021
CC 39 (3.68) 35 (2.8) 1.40 (0.88–2.24) 0.156 1.41(0.88–2.25) 0.150
CG+CC 368 (34.75) 370 (29.8) 1.25 (1.05–1.49) 0.012
d 1.26 (1.05–1.50) 0.011
d
Allele G 1,711 (80.8) 2,075 (83.7) 1.00 1.00
C 407 (19.2) 405 (16.3) 1.22 (1.05–1.42) 0.01
f 1.22 (1.05–1.42) 0.01
f
Combined effect of risk alleles
0 579 (54.67) 772 (62.3) 1.00 0.0011
c 1.00
1–2 421 (39.75) 413 (33.3) 1.36 (1.14–1.62) 0.0005 1.36 (1.14–1.62) 0.0005
3–4 59 (5.57) 55 (4.4) 1.43 (0.97–2.09) 0.07 1.43 (0.97–2.09) 0.07
Ptrend=0.0002 Ptrend
b=0.0002
0 579 (54.67) 772 (62.3) 1.00 1.00
$1 480 (45.33) 468 (37.7) 1.37 (1.16–1.62) 0.0002 1.37 (1.16–1.62) 0.0002
GA, gastric adenocarcinoma; SNP, single-nucleotide polymorphism; CI, confidence interval; OR, odds ratio.
aChi square test for genotype distributions between cases and controls.
bAdjusted for age, sex, smoking status and drinking status in logistic regress models.
cfor additive genetic models.
dfor dominant genetic models.
fat allelic levels.
The results were in bold, if the 95% CI excluded 1 or P,0.05.
doi:10.1371/journal.pone.0031932.t002
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To identify a possible association of rs2274223 and rs11187870
with PLCE1 mRNA levels, we further analyzed PLCE1 expression
levels of tumor and adjacent noncancerous tissues from patients
with different genotypes. A total of 48 gastric cancer tissues and
corresponding normal noncancerous tissues were subjected to the
real-time PCR to quantify PLCE1 transcript levels. As shown in
Figure 2A, the expression levels of PLCE1 mRNA was significantly
lower in tumors than in adjacent noncancerous tissues in all
samples, about 0.41 fold compared with noncancerous tissues.
(0.01960.002 vs. 0.00860.001, P,0.05). A higher expression
level of PLCE1 mRNA levels was observed in both AG and GG
carriers for rs2274223 in the controls (about 1.22 fold in AG
carriers and 1.09 fold in GG carriers versus AA carriers) but a
lower level in the GG carriers of the cases, compared to that of the
AA carriers of the cases. As shown in Figure 2B, the expression of
PLCE1 by genotypes of rs11187870 was very close to that of
rs2274223, and there was no significant difference in PLCE1
expression among the three genotypes in adjacent normal tissues.
Because the risk associated with the combined rs2274223
variant AG/GG genotypes and rs11187870 variant CG/CC
genotypes was more evident in subjects with cardia cancer, we also
compared the PLCE1 expression in subtypes of cardia gastric
cancer and non-cardia gastric cancer. In cardia gastric cancer, GG
carriers showed a higher expression of PLCE1(1.08 fold, compared
with that AA carriers; P=0.91), while in noncardia gastric cancer,
AG carriers showed a 1.52 fold higher expression of PLCE1 than
that of the AA carriers (P=0.96) (Figure 2C).
Discussion
In this case-control study, we investigated the associations of two
novel, potentially functional SNPs, one located in exon 26
(rs2274223A.G) and the other located in the 39 UTR
(rs11187870G.C) of PLCE1, with risk of gastric cancer in an
eastern Chinese population. The variant genotypes of each SNP
were associated with increased risk of gastric cancer, and this risk
was more evident in subgroups of males, non-smokers, non-
drinkers and patients with gastric cardia adenocarcinoma. In the
combined analysis, the joint effect of risk alleles contributed to the
risk of gastric cancer in an allele dose-response manner. Therefore,
our findings support the hypothesis that potentially functional
Figure 1. Forest plot showing associations between PLCE1 rs2274223 and gastric cancer risk. A) The ORs and 95% CIs were obtained
using AG vs. AA. B) The ORs and 95% CIs were obtained using GG vs. AA. The axis corresponds to the OR. The diamonds and the horizontal bars
represent the overall ORs with 95% CIs given by their width.
doi:10.1371/journal.pone.0031932.g001
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This finding is consistent with that reported in two recent GWASs
of northern Chinese populations [13,14] and another independent
replication study [15].
The PLCE1 gene is a member of the phospholipase C family
[22,23,24]. The PLCE1 protein contains one CDC25 domain at
its amino terminus that functions as a GEF for H-Ras and/or
Rap1. Two RA domains located at the carboxyl terminus of
PLCE1 are associated with H-Ras and Rap1A in a GTP-
dependent manner. These structural features suggest that PLCE1
is regulated downstream of the Ras superfamily GTPases [25,26].
PLCE1 catalyzes the hydrolysis of polyphosphoinositides into two
intracellular second messengers, such as inositol-1,4,5 trispho-
sphate (IP3) and diacylglycerol (DAG) that are involved in calcium
mobilization and protein kinase C activation, respectively [25,27].
Therefore, PLCE1 acts as an effector of the Ras family small
GTPases and thus plays an important role in regulating cell
growth, differentiation and development. There is evidence that
PLCE1 may be associated with pathogenesis; for example,
positional cloning revealed that mutations in PLCE1 were
responsible for the early-onset nephrotic syndrome [28] and that
the relatively frequent mutations in PLCE1 might cause isolated
diffuse mesangial sclerosis (IDMS)[29]. Recent studies also have
shown that PLCE1 could play crucial roles in intestinal
tumorigenesis and skin tumor formation [30,31]. It is likely that
the PLCE1 may play a role in tumorigenesis by a mechanism of
augmentation of angiogenesis and inflammation responses [30,31].
To date, only two recent GWASs [13,14] and a replication study
[15] have investigated the association between genetic variations of
PLCE1 and susceptibility to gastric cancer.
Table 3. Stratification analysis for associations between PLCE1 variant genotypes and GA risk.
Variables
rs2274223
(cases/controls)
Adjusted OR
a
(95% CI) P
a
rs11187870
(cases/controls)
Adjusted OR
a
(95% CI) P
a
Combined effect
of risk alleles
(cases/controls)
Adjusted OR
a
(95% CI) P
a
AA AG/GG GG CG/CC 0 $1
Age, yr
#58 (median) 302/380 205/193 1.33 (1.03–1.70) 0.027 349/413 158/160 1.16 (0.88–1.49) 0.312 293/370 214/203 1.32 (1.03–1.69) 0.028
.58 (median) 298/411 254/256 1.37 (1.09–1.73) 0.007 342/457 210/210 1.35 (1.06–1.71) 0.014 286/402 266/265 1.42 (1.13–1.78) 0.003
Gender
Males 417/530 335/313 1.37 (1.12–1.67) 0.002 482/593 270/250 1.33 (1.08–1.65) 0.007 401/516 351/327 1.39 (1.14–1.69) 0.001
Females 183/261 124/136 1.33 (0.97–1.82) 0.075 209/277 98/120 1.08 (0.78–1.50) 0.652 178/256 129/141 1.35 (0.99–1.84) 0.062
Smoking status
Never 362/526 294/293 1.45 (1.17–1.79) ,0.001 423/576 233/243 1.30 (1.04–1.62) 0.020 348/517 308/302 1.51 (1.22–1.86) ,0.001
Ever 238/265 165/156 1.18 (0.88–1.56) 0.271 268/294 135/127 1.17 (0.87–1.58) 0.300 231/255 172/166 1.15 (0.86–1.52) 0.349
Drinking status
Never 462/651 358/364 1.38 (1.14–1.66) ,0.001 536/708 284/307 1.22 (1.00–1.48) 0.049 446/636 374/379 1.40 (1.16–1.69) ,0.001
Ever 138/140 101/85 1.27 (0.86–1.87) 0.225 155/162 84/63 1.46 (0.97–2.21) 0.069 133/136 106/89 1.29 (0.88–1.89) 0.194
Tumor site
Cardia 129/791 155/449 2.07(1.59–2.70) ,0.001 158/870 126/370 1.86(1.42–2.43) ,0.001 124/772 160/468 2.08(1.59–2.7) ,0.001
Non-cardia 479/791 296/449 1.10(0.92–1.33) 0.30 549/870 226/370 0.98(0.81–1.20) 0.87 467/772 308/468 1.10(0.92–1.33) 0.03
GA, gastric adenocarcinoma; SNP, single-nucleotide polymorphism; CI, confidence interval; OR, odds ratio.
aObtained in logistic regression models with adjustment for age, sex, smoking status and drinking status.
The results were in bold, if the 95% CI excluded 1 or P,0.05.
doi:10.1371/journal.pone.0031932.t003
Table 4. Haplotype analysis for genotypes of PLCE1 and GC risk.
PLCE1 haplotypes
a Haplotype frequencies
Crude OR
(95% CI)
Adjusted OR
a
(95% CI) P
a
Cases
(N=2,118)
Controls
(N=2,480)
N% N%
Ars2274223Grs11187870 1575 74.4 1950 78.6 1.00 1.00
Grs2274223Crs11187870 383 18.1 383 15.4 1.24 (1.06–1.45) 1.24 (1.06–1.45) 0.007
Grs2274223Grs11187870 136 6.4 125 5.0 1.35 (1.05–1.73) 1.34 (1.04–1.72) 0.024
Ars2274223Crs11187870 24 1.1 22 0.9 1.35 (0.75–2.42) 1.33 (0.74–2.38) 0.344
aObtained in logistic regression models with adjustment for age, sex, smoking status and drinking status.
The results were in bold, if the P value was significant.
doi:10.1371/journal.pone.0031932.t004
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between the PLCE1 rs2274223A.G SNP and gastric cancer
susceptibility [13,14,15]. Our mini-meta analysis results showed
that the risk estimates of the AG or GG genotype vs. the AA
genotype in our study were similar to that of the other three
published studies. In addition, the 39 UTR rs11187870G.C SNP
of PLCE1 was identified for the first time to be associated with
increased risk of gastric cancer, although this SNP is in incomplete
LD with rs2274223A.G. It is likely that this SNP in the 39UTR
may disrupt the microRNA–mRNA interaction and affect
expression of the microRNA targets [32,33]. In the combined
analysis, subjects who carried more risk alleles (i.e., rs2274223G
and rs11187870C) of PLCE1 showed a higher risk of gastric
cancer, suggesting a joint effect of these two SNPs on gastric
cancer susceptibility. In further logistic regression analysis by
simultaneously adjusting for each of the two loci, only the risk
associated with rs2274223 remained statistically significant, which
may reflect the fact that rs11187870 is in incomplete LD with
rs2274223. In the haplotype analysis, compared with the most
common Ars2274223Grs11187870 haplotype, the Grs2274223Crs11187870
and Grs2274223Grs11187870 haplotypes were strongly associated with
an increased risk of gastric cancer. Taken together, the potentially
functional rs2274223G and rs11187870C alleles are most likely to
be responsible for the observed risk associated with genetic
variations in PLCE1.
In the stratified analysis, the combined effect of rs2274223 and
rs11187870 SNPs was more evident in males, non-smokers, non-
drinkers and cardia adenocarcinomas. These findings are
consistent with the concept of genetic susceptibility, in which
individuals at risk are likely to develop cancer when they have
been exposed to a low level of exposure. There are several
possibilities for such findings. First of all, by definition, ‘‘non-
smokers’’ and ‘‘non-drinkers’’ were those who may have exposed
to low levels of smoking or alcohol, and never smokers may have
been exposed to passive smoking or other unknown carcinogens in
the environment. For smokers and drinkers, the effect of genetic
variations may be overwhelmed by the strong impact of
environmental carcinogens. In contrast, for those who exposed
to low levels of smoking or alcohol, genetic variations may play a
dominant role in the initiation of carcinogenesis. Secondly, our
study is still not large enough to provide enough statistical power
to detect any gene-environment interaction. Therefore, larger
population-based studies, preferably with detailed information
about passive smoking, are required to further validate our
findings. As cancer is a complex and multifactorial disease, gene-
gene and gene-environment interactions may occur, and a single
genetic variant is insufficient to predict the overall risk. Thus,
future studies should include more functional SNPs in PLCE1 or in
other related genes in the similar biological pathways that may be
involved in the etiology of gastric cancer.
To verify whether rs2274223 would affect PLCE1 expression
and thus play a role in the etiology of gastric cancer, we used the
real-time PCR to measure PLCE1 expression at the mRNA level.
Overall, the mRNA expression level was much lower in the tumors
than in the adjacent normal tissues, which was consistent with two
separate studies on colorectal carcinoma [34,35]. In these two
studies, over-expression of PLCE1 caused a higher rate of cell
death, inhibition of proliferation or promoted apoptosis in
colorectal tumor cells, indicating that PLCE1 might negatively
regulate viability and proliferation of colorectal tumor cells and
thus might act as a tumor suppressor gene [34,35]. In the present
study, there was a non-significantly higher expression of PLCE1
mRNA in AG and GG carriers than in AA carriers in the controls;
however, such a difference did not show in the GG carriers of the
cases. This discrepancy is either due to limited samples used for the
detection or the cases with the GG genotype may have other
unknown defects, such as lost of heterozygosis, because the GG
genotype was associated with much lower PLCE1 expression in the
cases but not in the controls. Meanwhile, higher expression was
observed in subjects carrying the AG genotype but not the GG
genotype. This may be due to the relative small sample size for the
real time PCR analysis or there were some unknown mechanisms,
e.g., PLCE1 may be regulated by other genes involved in cell
growth and differentiation. The expression levels of PLCE1 were
also different between cardia and noncardia tumors, that is, there
was a higher expression level in GG carriers in cardia cases but a
higher expression in AG carriers in noncarida cases. This may also
be due to the limited sample size of cardia cases. Therefore, the
Figure 2. Real-time PCR quantification of expression of PLCE1
mRNA in tumor and corresponding normal noncancerous
tissues. *P,0.05, **P,0.01. A. PLCE1 mRNA expression in tumor and
corresponding normal noncancerous tissues in total samples and
samples stratified by different genotypes of rs2274223. B. PLCE1 mRNA
expression in tumor and corresponding normal noncancerous tissues in
total samples and samples stratified by different genotypes of
rs11187870. C. PLCE1 mRNA expression of different genotypes for
rs2274223 and rs11187870 in normal noncancerous tissues in tumor site
of cardia and noncardia.
doi:10.1371/journal.pone.0031932.g002
PLCE1 Variants and Risk of Gastric Adenocarcinoma
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polymorphism in our study, suggesting that some unknown
consequences of the polymorphism, rather than a quantitative
change, may be associated with the development of gastric cancer.
It is also possible that the expression of PLCE1 may be linked to
some other polymorphisms within PLCE1 or elsewhere in the
genome, as well as some other factors that may enhance or repress
its expression. In addition, the sample size of the current study was
relatively small, and larger study is needed to confirm the results of
our present study and better clarify the implication of the genetic
background of PLCE1 on the development of gastric cancer.
Several limitations of our study need to be addressed. Firstly,
this was a hospital-based case-control study with patients from
hospitals and controls from the community, and thus selection bias
cannot be completely excluded. However, potential confounding
bias may be minimized by frequency-matching cases and controls
on age, sex, areas of residence and further adjustment for potential
confounding factors in final analyses. Second, the sample size of
our study was moderate, and the statistical power of the study may
be limited, particularly for the stratified analysis and detection of
gene-environmental interactions, although our mini-meta analysis
suggested that the risk estimate of variant genotype in our study
was very close to that of other published studies. Third, only two
potentially functional SNPs of PLCE1 were genotyped in this
study, which did not cover all variants of PLCE1 and restricted
further haplotype analysis. Fourth, the functional analysis in the
form of mRNA expression levels may be rudimentary, further
functional analysis with immunohistochemistry for rs2274223 in
exon and plasmid construction for luciferase assay for rs11187870
in 39UTR are needed to unravel the underlying mechanism.
Finally, information on other exposures, such as dietary intake,
occupational exposure and Helicobacter pylori infection, were not
available for analysis. Future studies need to address whether these
factors interact with genetic variants in PLCE1 in the etiology of
gastric cancer.
In conclusion, in this case-control study of gastric cancer in an
eastern Chinese population, we provided statistical evidence that
confirmed the associations between the reported PLCE1
rs2274223, as well as the novel rs11187870, and risk of gastric
cancer. Consistently, the combined effect of these two SNPs and
their estimated haplotypes were also associated with gastric cancer
risk, suggesting that genetic variations in the PLCE1 gene may play
a role in the development of gastric cancer. However, these
findings call for larger and more in-depth molecular studies that
are needed to unravel the role of rs2274223G and rs11187870C
alleles in the etiology of gastric cancer.
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